Acquisition Pending

Rallybio acquisition of Candid Therapeutics

Announced 2 Mar 2026

Advisers

Candid Therapeutics

Target

Financial adviser
Legal adviser

Rallybio

Acquirer

Financial adviser
Legal adviser
Target
Candid Therapeutics
Acquirer
Rallybio
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development

In the league tables

Similar deals

All biotech deals →

Competing proposals

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.